Search Clinical Trials
Clinical Trial Listings
Volunteer
Learn About Clinical Trials

Asahikwa, Japan

Search

Location

Distance

< 2 Miles

Filters

Type

Remote

On Site

Actively recruiting

Accepts healthy volunteers

Location

Distance

< 2 Miles

< 5 Miles

< 10 Miles

< 20 Miles

< 30 Miles

< 40 Miles

< 50 Miles

Entire World

Age

0

0

Gender

Male

Female

Trial Phase

Phase 1

Phase 2

Phase 3

Phase 4

Sponsor

Alx Oncology Inc.

Abbvie

Anthos Therapeutics, Inc.

Areteia Therapeutics

Astellas Pharma Global Development, Inc.

Astellas Pharma Inc

Astrazeneca

Avidity Biosciences, Inc.

Bayer

Beigene

Biogen

Boehringer Ingelheim

Boston Scientific Corporation

Bristol-myers Squibb

Cg Oncology, Inc.

Celgene

Chimerix

Chinese University Of Hong Kong

Featured
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Phase
1/2
Span
163 weeks
Sponsor
Incyte Corporation
Osaka-Shi
Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**
Phase
3
Span
Sponsor

Osaka-Shi
Recruiting
Featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

Phase
2
Span
Sponsor

Osaka-Shi
Recruiting
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Phase
2
Span
155 weeks
Sponsor
GlaxoSmithKline
Osaka
Recruiting
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Phase
2
Span
151 weeks
Sponsor
Eisai Inc.
Osaka
Recruiting
ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.
Phase
3
Span
238 weeks
Sponsor
Ono Pharmaceutical Co. Ltd
Osaka
Recruiting
Specified Drug-use Surveillance of Fabhalta Capsules
The observation period will be 48 weeks after the start of treatment with Fabhalta. For patients in whom treatment with Fabhalta is discontinued within 48 weeks after the start of the treatment, adverse events occurring by the last day of the treatment + 30 days and concomitant drugs will be monitored and recorded in CRFs.
Phase
N/A
Span
211 weeks
Sponsor
Novartis Pharmaceuticals
Osaka
Recruiting
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
Phase
2
Span
110 weeks
Sponsor
Eli Lilly and Company
Osaka
Recruiting
Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings
Phase
N/A
Span
153 weeks
Sponsor
Ferring Pharmaceuticals
Osaka
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Phase
3
Span
161 weeks
Sponsor
Pfizer
Osaka
Recruiting

1-10 of 232

212 Carnegie Center, Suite 301
Princeton, NJ 08540, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

Disclaimer
Privacy Policy
Term of Use
Do Not Sell My Personal Information